MCID: STR015
MIFTS: 40

Stereotypic Movement Disorder

Categories: Mental diseases

Aliases & Classifications for Stereotypic Movement Disorder

MalaCards integrated aliases for Stereotypic Movement Disorder:

Name: Stereotypic Movement Disorder 12 41 14 69
Stereotyped Repetitive Movements Nos 12
Stereotypy Habit Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2303
ICD10 32 F98.4
ICD9CM 34 307.3
MeSH 41 D019956
SNOMED-CT 64 5507002
UMLS 69 C0038273

Summaries for Stereotypic Movement Disorder

Disease Ontology : 12 A specific developmental disorder that is characterized by repeated, rhythmic, purposeless movements or activities such as head banging, nail biting, or body rocking.

MalaCards based summary : Stereotypic Movement Disorder, also known as stereotyped repetitive movements nos, is related to trichotillomania and parasomnia, sleep bruxism type, and has symptoms including recurrent muscle twitches (symptom), involuntary movements and tremor. An important gene associated with Stereotypic Movement Disorder is PRL (Prolactin). The drugs Aripiprazole and Cycloserine have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and testes, and related phenotype is behavior/neurological.

Wikipedia : 72 Stereotypic movement disorder (SMD) is a motor disorder with onset in childhood involving repetitive,... more...

Related Diseases for Stereotypic Movement Disorder

Graphical network of the top 20 diseases related to Stereotypic Movement Disorder:



Diseases related to Stereotypic Movement Disorder

Symptoms & Phenotypes for Stereotypic Movement Disorder

UMLS symptoms related to Stereotypic Movement Disorder:


recurrent muscle twitches (symptom), involuntary movements, tremor, myoclonus, muscular fasciculation, clonus, athetosis

MGI Mouse Phenotypes related to Stereotypic Movement Disorder:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.1 NPY PRL SLITRK1 TAC1 CCK MECP2

Drugs & Therapeutics for Stereotypic Movement Disorder

Drugs for Stereotypic Movement Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 124)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
2
Cycloserine Approved Phase 4 68-41-7 6234 401
3
Dextromethorphan Approved Phase 4 125-71-3 5362449 5360696
4
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
5
Menthol Approved Phase 4,Phase 1 2216-51-5 16666
6 Antipsychotic Agents Phase 4,Phase 3
7 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
8 Pharmaceutical Solutions Phase 4,Phase 2
9 Psychotropic Drugs Phase 4,Phase 3,Phase 2
10 Tranquilizing Agents Phase 4,Phase 3
11 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
12 Anti-Infective Agents Phase 4
13 Excitatory Amino Acid Antagonists Phase 4
14 Excitatory Amino Acids Phase 4
15 Anti-Bacterial Agents Phase 4
16 Antibiotics, Antitubercular Phase 4
17 Antimetabolites Phase 4
18 Antitubercular Agents Phase 4
19 Antitussive Agents Phase 4
20 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
21 Renal Agents Phase 4
22 Respiratory System Agents Phase 4
23
Sertraline Approved Phase 3,Phase 2 79617-96-2 68617
24
Dopamine Approved Phase 3,Phase 2 51-61-6, 62-31-7 681
25
Methylphenidate Approved, Investigational Phase 3 20748-11-2, 113-45-1 4158
26
Oxytocin Approved, Vet_approved Phase 2, Phase 3 50-56-6 53477758 439302
27
Acamprosate Approved, Investigational Phase 2, Phase 3 77337-76-9 71158
28
Ethanol Approved Phase 2, Phase 3 64-17-5 702
29 Antidepressive Agents Phase 3,Phase 2
30 Neurotransmitter Uptake Inhibitors Phase 3,Phase 2
31
Serotonin Phase 3,Phase 2 50-67-9 5202
32 Serotonin Agents Phase 3,Phase 2
33 Serotonin Uptake Inhibitors Phase 3,Phase 2
34 Central Nervous System Stimulants Phase 3
35 Dopamine Agents Phase 3,Phase 2
36 Dopamine Uptake Inhibitors Phase 3
37 Oxytocics Phase 2, Phase 3
38
Desipramine Approved, Investigational Phase 2 50-47-5 2995
39
Citalopram Approved Phase 2 59729-33-8 2771
40
Donepezil Approved Phase 2 120014-06-4 3152
41
Methyltestosterone Approved Phase 2 58-18-4 6010
42
Oxandrolone Approved, Investigational Phase 2 53-39-4 5878
43
Testosterone Approved, Investigational Phase 2 58-22-0 6013
44
Bromocriptine Approved, Investigational Phase 2 25614-03-3 31101
45
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
46 Orange Approved, Nutraceutical Phase 2
47
Melatonin Approved, Nutraceutical, Vet_approved Phase 2 73-31-4 896
48
Vitamin C Approved, Nutraceutical Phase 2 50-81-7 54670067 5785
49
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
50
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006

Interventional clinical trials:

(show top 50) (show all 88)

# Name Status NCT ID Phase Drugs
1 Study to Evaluate the Efficacy and Safety of Aripiprazole Unknown status NCT02069977 Phase 4 Aripiprazole
2 Enhancing STDP After Spinal Cord Injury Recruiting NCT02701777 Phase 4 Seromycin;Dextromethorphan;Seromycin Placebo;Dextromethorphan Placebo
3 Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes Enrolling by invitation NCT03333629 Phase 4
4 Repetitive Behavior Disorders in People With Severe Mental Retardation Unknown status NCT00491478 Phase 3 sertraline
5 Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders Completed NCT00870727 Phase 3 Aripiprazole oral product;Placebo oral capsule
6 Use of Acupuncture In Children With Autistic Spectrum Disorder Completed NCT00346736 Phase 3
7 Akathisia (Restless Legs Syndrome) in People With Schizophrenia and Mental Retardation Completed NCT00065286 Phase 3
8 A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms Completed NCT00541346 Phase 3 Methylphenidate Transdermal System
9 Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD) Completed NCT00365859 Phase 3 Aripiprazole
10 Study of Acamprosate in Autism Recruiting NCT01813318 Phase 2, Phase 3 Acamprosate;Placebo
11 Oxytocin in Adolescents With Autism Spectrum Disorders Suspended NCT02007447 Phase 2, Phase 3 OCYTOCINA - SPRAY NASAL
12 Reducing Internalized Stigma in People With Serious Mental Illness Completed NCT01259427 Phase 2
13 Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome Completed NCT00990691 Phase 2 Administration of a high dose of desipramine;Administration of a low dose of desipramine;Administration of a placebo
14 Intranasal Oxytocin Treatment for Social Deficits in Children With Autism Completed NCT01624194 Phase 2 Oxytocin nasal spray;Placebo
15 Transcranial Electrical Polarization to Treat Focal Hand Dystonia Completed NCT00106782 Phase 2
16 Motor Training to Treat Hand Dystonia Completed NCT00021853 Phase 2
17 Deep Brain Stimulation for Cervical Dystonia Completed NCT00105430 Phase 2
18 Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome Completed NCT00114634 Phase 2
19 Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome Completed NCT01253629 Phase 2 AFQ056;Placebo
20 Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome Completed NCT01357239 Phase 2 AFQ056;Placebo
21 Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder Completed NCT01694667 Phase 2 Omega-3 Fatty Acids
22 Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1) Completed NCT00086645 Phase 2 citalopram hydrobromide
23 Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder Recruiting NCT02909959 Phase 2 Sulforaphane;Placebo
24 Pilot Study of Sleep Therapy and Biomarkers in Children With Autism Spectrum Disorders Recruiting NCT02487082 Phase 2 Melatonin and Donepezil
25 Androgen Effect on Klinefelter Syndrome Motor Outcome Active, not recruiting NCT00348946 Phase 2 androgen oxandrolone
26 Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis Suspended NCT00004300 Phase 2 bromocriptine;sertraline hydrochloride
27 A Folinic Acid Intervention for Autism Spectrum Disorders Terminated NCT01602016 Phase 2 Folinic Acid and placebo;Folinic Acid
28 Motor and Premotor Cortex Stimulation for Treatment of Secondary Focal Dystonia With Striato Palliadal Lesion : Evaluation of Safety and Effectiveness Completed NCT00505323 Phase 1
29 Deep Brain Stimulation to Treat Cervical Dystonia Completed NCT00132340 Phase 1
30 Study of Chiropractic and Neuromuscular Reeducation as a Treatment for Autism Symptoms Terminated NCT01996800 Phase 1
31 Osteoconduction Potential of an Injectable Calcium Phosphate in Orthopaedic Surgery in Fillings of Osseous Defects Unknown status NCT00206791
32 Effects of Hyperbaric Oxygenation Therapy on Adaptive, Aberrant and Stereotyped Behaviors in Children With Autism Unknown status NCT00404846
33 Neuropsychopathological Study of Autism Unknown status NCT01677663
34 Cerebral Activity Related to Primary Motor Stereotypies in Children: An EEG Study. Completed NCT01037361
35 Use of Functional Behavioral Assessments to Evaluate Stereotypy and Repetitive Behaviors in a Double-blind, Placebo Controlled Trials of Various Medications Used to Treat Children With Autism. Completed NCT00211770
36 "EASY EFFECTIVE SMOKELESS" With NICORETTE® Completed NCT01323491 Nicotine replacement therapy
37 Ending Self Stigma for PTSD Completed NCT02734212
38 Trial of Vitamin D3 Supplementation in Paediatric Autism Completed NCT02508922
39 Use of a Visual Pedagogy and Structure With Children With Autism for Routine Physical Exams Completed NCT03232775
40 An Intervention to Improve Communication Between Physicians and Minority Patients With Hypertension Completed NCT01037920
41 Study Evaluating the Nasopharyngeal Carriage in Healthy Children Completed NCT00768833
42 Study of the Preliminary Effect of TEVAW: a Program to Address Intimate Partner Violence in Northern Tanzania Completed NCT02434796
43 LINE: Treatment Patterns in postmenopausaL Women With Hormone Receptor Positive Breast Cancer Completed NCT01561443
44 Robot-Aided Neurorehabilitation of the Upper Extremities Completed NCT02434237
45 Upper Limb Evaluation in Non Ambulatory Patients With Neuromuscular Disorder Completed NCT00993161
46 Activity in Tourette Syndrome Completed NCT02153463
47 Effectiveness of a Dissonance-Based Eating Disorder Prevention Program (The Body Project II) Completed NCT00663754
48 Eating Disorder Prevention Programs Completed NCT00042185
49 Using the Prevent-Teach-Reinforce Model to Reduce Problem Behaviors in Children With Autism Spectrum Disorders Completed NCT02153203
50 Comparative Evaluation of Gabapentine and Occlusal Splint in the Management of Sleep Bruxism Completed NCT01255878 Gabapentine

Search NIH Clinical Center for Stereotypic Movement Disorder

Cochrane evidence based reviews: stereotypic movement disorder

Genetic Tests for Stereotypic Movement Disorder

Anatomical Context for Stereotypic Movement Disorder

MalaCards organs/tissues related to Stereotypic Movement Disorder:

38
Brain, Eye, Testes, Spinal Cord, Cortex, Bone, Skin

Publications for Stereotypic Movement Disorder

Articles related to Stereotypic Movement Disorder:

(show all 14)
# Title Authors Year
1
GRIN1 mutations cause encephalopathy with infantile-onset epilepsy, and hyperkinetic and stereotyped movement disorders. ( 25864721 )
2015
2
Stereotypic movement disorder: a case for Procrustes? ( 25039962 )
2014
3
Cheek-biting disorder: another stereotypic movement disorder? ( 21889295 )
2011
4
Trichotillomania (hair pulling disorder), skin picking disorder, and stereotypic movement disorder: toward DSM-V. ( 20533371 )
2010
5
Stereotypic movement disorder: easily missed. ( 20187883 )
2010
6
Low dimensional temporal organization of spontaneous eye blinks in adults with developmental disabilities and stereotyped movement disorder. ( 19819672 )
2010
7
Escitalopram treatment of stereotypic movement disorder in an adolescent with mitochondrial disorder and mental retardation. ( 19519269 )
2009
8
Is trichotillomania a stereotypic movement disorder? An analysis of body-focused repetitive behaviors in people with hair-pulling. ( 19034750 )
2008
9
Trichotillomania, stereotypic movement disorder, and related disorders. ( 17880861 )
2007
10
Stereotypic movement disorder after acquired brain injury. ( 12097226 )
2002
11
Opiate sensitivity test in patients with stereotypic movement disorder and trichotillomania. ( 12369265 )
2002
12
Characteristics of stereotypic movement disorder and self-injurious behavior assessed with the Diagnostic Assessment for the Severely Handicapped (DASH-II). ( 9403928 )
1997
13
Stereotypic movement disorder. ( 9164434 )
1997
14
DSM-IV stereotypic movement disorder: persistence of stereotypies of infancy in intellectually normal adolescents and adults. ( 8617696 )
1996

Variations for Stereotypic Movement Disorder

Expression for Stereotypic Movement Disorder

Search GEO for disease gene expression data for Stereotypic Movement Disorder.

Pathways for Stereotypic Movement Disorder

GO Terms for Stereotypic Movement Disorder

Cellular components related to Stereotypic Movement Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.02 CCK NPY PRL SLITRK1 TAC1

Biological processes related to Stereotypic Movement Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.61 CCK NPY PRL
2 neuropeptide signaling pathway GO:0007218 9.48 NPY TAC1
3 negative regulation of angiogenesis GO:0016525 9.46 MECP2 PRL
4 regulation of blood pressure GO:0008217 9.4 NPY TAC1
5 positive regulation of synapse assembly GO:0051965 9.37 MECP2 SLITRK1
6 synapse assembly GO:0007416 9.32 MECP2 SLITRK1
7 sensory perception of pain GO:0019233 9.26 MECP2 TAC1
8 long-term memory GO:0007616 9.16 MECP2 TAC1
9 chemical synaptic transmission GO:0007268 9.13 MECP2 NPY TAC1
10 behavioral fear response GO:0001662 8.62 CCK MECP2

Molecular functions related to Stereotypic Movement Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 8.96 CCK NPY
2 hormone activity GO:0005179 8.8 CCK NPY PRL

Sources for Stereotypic Movement Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....